InspireMD, Inc. (NSPR)
| Previous close | 1.9000 |
| Open | 1.8100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.8100 - 1.9499 |
| 52-week range | 1.0300 - 3.8500 |
| Volume | |
| Avg. volume | 34,958 |
| Market cap | 44.857M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8200 |
| Earnings date | 14 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
GlobeNewswireInspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024. Presentation details: Date:Wednesday, April 10th Time:8:00-8:40 AM ET Webcast:https://wsw.com/webcast/needham13
Simply Wall St.InspireMD's (NASDAQ:NSPR) investors will be pleased with their solid 110% return over the last year
It hasn't been the best quarter for InspireMD, Inc. ( NASDAQ:NSPR ) shareholders, since the share price has fallen 16...
- GlobeNewswire
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig,
